3.67Open3.67Pre Close0 Volume10 Open Interest90.00Strike Price0.00Turnover297.29%IV65.98%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier22DDays to Expiry3.67Extrinsic Value100Contract SizeAmericanOptions Type-0.0369Delta0.0004Gamma69.14Leverage Ratio-0.3346Theta-0.0071Rho-2.55Eff Leverage0.0503Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet